Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521602 | 0.80 | LMNA (0.31) | — | |
| SCHEMBL5521606 | 0.80 | LMNA (0.31) | — | |
| SCHEMBL19836573 | 0.79 | OPRK1 (0.32) | ELANE | |
| Hydrochloric Acid SCHEMBL5074295 | 0.79 | KDM4E (0.35) | — | |
| SCHEMBL19914256 | 0.78 | HTT (0.43) | ELANE | |
| Hydrochloric Acid SCHEMBL5074297 | 0.77 | — | — | |
| SCHEMBL21097534 | 0.77 | CRHR1 (0.36) | ELANE | |
| SCHEMBL14510191 | 0.76 | ADRB1 (0.37) | — | |
| SCHEMBL14758281 | 0.75 | PLK4 (0.36) | ELANE | |
| SCHEMBL24869551 | 0.72 | CBLB (0.38) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | ELANE 2529/4885 |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | ELANE 2529/4885 |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | ELANE 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.